Close

Aastrom Bio (ASTM) Grantd Key Australian Patent for Ixmyelocel-T

Go back to Aastrom Bio (ASTM) Grantd Key Australian Patent for Ixmyelocel-T

Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia

December 19, 2013 9:03 AM EST

ANN ARBOR, Mich., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that it has been granted a key composition-of-matter patent from the Australian Patent Office for ixmyelocel-T, Aastrom's cell therapy product candidate.

The issued patient, entitled "Mixed Cell Populations for Tissue Repair and Separation Technique for Cell Processing," provides protection for key characteristics of ixmyelocel-T through 2027. Aastrom now holds patent protection for ixmyelocel-T in Australia, the United States and the European Union.

"Patent... More